Quick Takeaways
- This page summarizes James C. Hamilton's Form 4 filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 04 Sep 2025, 17:37.
James C. Hamilton - 02 Sep 2025 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
- Signature
- /s/James Hamilton
- Issuer symbol
- ARWR
- Transactions as of
- 02 Sep 2025
- Net transactions value
- -$375,000
- Form type
- 4
- Filing time
- 04 Sep 2025, 17:37:01 UTC
- Previous filing
- 15 Aug 2025
- Next filing
- 16 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"James C. Hamilton filed Form 4 for ARROWHEAD PHARMACEUTICALS, INC. (ARWR) on 04 Sep 2025."
What Changed
- Previous filing in this sequence was filed on 15 Aug 2025.
- Current net transaction value: -$375,000.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Hamilton James C | Chief Medical Officer | 177 EAST COLORADO BLVD, SUITE 700, PASADENA | /s/James Hamilton | 04 Sep 2025 | 0001830755 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ARWR | Common Stock | Sale | $375,000 | -15,000 | -5.7% | $25.00 | 247,122 | 02 Sep 2025 | Direct | F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| F2 | Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |